Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

510(k) Sponsors Should Be Wary Of Informal Talk With FDA, Attorney Says

This article was originally published in The Gray Sheet

Executive Summary

Informal communications via telephone or e-mail before or during a 510(k) submission can be an efficient approach for sponsors, but companies should be aware of the pitfalls, says Hogan & Hartson Partner and FDA device specialist John Smith

You may also be interested in...



Do-Over? FDA Orders Look-Back At Knee Device 510(k) Review Process

In a sign of the intense scrutiny CDRH is facing under the new administration, FDA is taking the rare step of performing an internal review of its decision process for a recently 510(k)-cleared device. The inquiry could potentially lead to a "reconsideration" of the clearance, the agency says

Making The Most Of FDA’s Pre-Market Process: Insiders Share Tips

In search of the latest insider tips on navigating FDA's pre-market review process, "The Gray Sheet" invited three experts to speak on the topic. They answered our questions during a panel discussion Oct. 24 at Windhover Information's 1In3 East meeting in Boston

FDA Gets “Interactive” In New Premarket Guidance Document

A Dec. 28 final FDA guidance document lays out a path for more informal interaction between agency reviewers and device companies while preserving CDRH's options to place holds on premarket reviews

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel